Skip to main content
SpringerLink
Log in
Book cover

Polypharmacy in Psychiatry Practice, Volume II pp 145–155Cite as

Metabolic Syndrome and Antipsychotic Polypharmacy

  • Chapter
  • First Online:

  • 1167 Accesses

Abstract

Patients with schizophrenia are more likely than the general population to have metabolic syndrome and to live around 15 fewer years largely because of cardiovascular death. Recent studies have suggested that antipsychotic polypharmacy may be associated with metabolic disturbance including metabolic syndrome and the mortality related to it. Although antipsychotic polypharmacy is not recommended and there is limited evidence of its benefits, it is nevertheless becoming common in the treatment of schizophrenia. If it is indeed associated with a greater risk of metabolic syndrome, then more widespread use is a serious concern. In this chapter, we review the effects of antipsychotic polypharmacy on mortality, metabolic disturbance, and metabolic syndrome. The results of earlier studies indicate that antipsychotic polypharmacy might increase the risk of some metabolic disturbances and related mortality but not the risk of metabolic syndrome. The effects of antipsychotic polypharmacy on metabolic disturbance and metabolic syndrome may be unchanged in patients with schizophrenia even after changing unhealthy lifestyles. Further studies are still needed to clarify the association between antipsychotic polypharmacy and metabolic disturbance or metabolic syndrome. At present, in cases when antipsychotic polypharmacy is deemed necessary, it is recommended that testing for metabolic parameters should be undertaken more often in patients receiving polypharmacy than in those receiving monotherapy and stricter lifestyle interventions are needed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

CI:

Confidence interval

HDL:

High-density lipoprotein

LDL:

Low-density lipoprotein

OR:

Odds ratio

RR:

Rate ratio

TG/HDL:

The triglycerides/high-density lipoprotein cholesterol ratio

References

  1. Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21):2709–2716

    Article  PubMed  Google Scholar 

  2. De Hert M, van Winkel R, Van Eyck D et al (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2:14

    Article  PubMed  Google Scholar 

  3. Hennekens CH, Hennekens AR, Hollar D et al (2005) Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150(6):1115–1121

    Article  PubMed  Google Scholar 

  4. Meyer JM, Stahl SM (2009) The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 119(1):4–14

    Article  PubMed  CAS  Google Scholar 

  5. Lehman AF, Lieberman JA, Dixon LB et al (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1–56

    PubMed  Google Scholar 

  6. Miller AL, Hall CS, Buchanan RW et al (2004) The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 65(4):500–508

    Article  PubMed  Google Scholar 

  7. Miller AL, Craig CS (2002) Combination antipsychotics: pros, cons, and questions. Schizophr Bull 28(1):105–109

    Article  PubMed  Google Scholar 

  8. Schumacher JE, Makela EH, Griffin HR (2003) Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37(7–8):951–955

    Article  PubMed  Google Scholar 

  9. Tapp A, Wood AE, Secrest L et al (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54(1):55–59

    Article  PubMed  Google Scholar 

  10. Rittmannsberger H, Meise U, Schauflinger K et al (1999) Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 14(1):33–40

    Article  PubMed  CAS  Google Scholar 

  11. Williams CL, Johnstone BM, Kesterson JG et al (1999) Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 37(4 Suppl Lilly):AS81–AS86

    Article  PubMed  CAS  Google Scholar 

  12. Procyshyn RM, Kennedy NB, Tse G et al (2001) Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 46(4):334–339

    PubMed  CAS  Google Scholar 

  13. Sim K, Su A, Fujii S et al (2004) Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58(2):178–183

    Article  PubMed  Google Scholar 

  14. Hida H, Faber M, Alberto-Gondouin MC et al (1997) Analysis of prescriptions for psychotropic drugs in a psychiatric hospital. Therapie 52(6):573–578

    PubMed  CAS  Google Scholar 

  15. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI et al (2005) A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66(1):63–72

    Article  PubMed  Google Scholar 

  16. Shiloh R, Zemishlany Z, Aizenberg D et al (1997) Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study. Eur Psychiatry 12(3):152–155

    Article  PubMed  CAS  Google Scholar 

  17. Montgomery J, Winterbottom E, Jessani M et al (2004) Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 65(11):1491–1498

    Article  PubMed  Google Scholar 

  18. Hollis J, Touyz S, Grayson D et al (2006) Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001. Aust N Z J Psychiatry 40(11–12):981–986

    Article  PubMed  Google Scholar 

  19. Joukamaa M, Heliovaara M, Knekt P et al (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188:122–127

    Article  PubMed  Google Scholar 

  20. Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325–329

    Article  PubMed  CAS  Google Scholar 

  21. Baandrup L, Gasse C, Jensen VD et al (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case–control study. J Clin Psychiatry 71(2):103–108

    Article  PubMed  Google Scholar 

  22. Nagamine T (2010) Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study. Neuropsychiatr Dis Treat 6:281–288

    PubMed  CAS  Google Scholar 

  23. Kessing LV, Thomsen AF, Mogensen UB et al (2010) Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 197(4):266–271

    Article  PubMed  Google Scholar 

  24. Honer WG, Thornton AE, Chen EY et al (2006) Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354(5):472–482

    Article  PubMed  CAS  Google Scholar 

  25. Weiner E, Conley RR, Ball MP et al (2010) Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 35(11):2274–2283

    Article  PubMed  CAS  Google Scholar 

  26. Fleischhacker WW, Heikkinen ME, Olie JP et al (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115–1125

    Article  PubMed  CAS  Google Scholar 

  27. Muscatello MR, Bruno A, Pandolfo G et al (2011) Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 127(1–3):93–99

    Article  PubMed  Google Scholar 

  28. Kane JM, Correll CU, Goff DC et al (2009) A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 70(10):1348–1357

    Article  PubMed  CAS  Google Scholar 

  29. Goodwin G, Fleischhacker W, Arango C et al (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus meeting, March 2008, Nice. Eur Neuropsychopharmacol 19(7):520–532

    Article  PubMed  CAS  Google Scholar 

  30. Riordan H, Antonini P, Murphy M (2011) Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and health care implications. Am Health Drug Benefits 4(5):292–302

    Google Scholar 

  31. Krane-Gartiser K, Breum L, Glumrr C et al (2011) Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry 65(5):345–352

    Article  PubMed  Google Scholar 

  32. Huang MC, Lu ML, Tsai CJ et al (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120(4):274–280

    Article  PubMed  Google Scholar 

  33. Correll CU, Frederickson AM, Kane JM et al (2007) Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 89(1–3):91–100

    Article  PubMed  Google Scholar 

  34. Connolly M, Kelly C (2005) Life style and physical health in schizophrenia. Adv Psychiatry Treat 11:125–132

    Article  Google Scholar 

  35. Misawa F, Shimizu K, Fujii Y et al (2011) Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 11:118

    Article  PubMed  Google Scholar 

  36. Silver H, Kogan H, Zlotogorski D (1990) Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 51(11):459–462

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yamanashi Prefectural KITA Hospital, Yamanashi, Japan

    Fuminari Misawa & Fujii Yasuo

  2. Department of Social Psychiatry, National Institute of Mental Health, Tokyo, Japan

    Yasuyuki Okumura & Hiroto Ito

Authors
  1. Fuminari Misawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fujii Yasuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuyuki Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroto Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fuminari Misawa .

Editor information

Editors and Affiliations

  1. Sha'ar Menashe Mental Health Center, Hadera, 38814, Israel

    Michael S. Ritsner

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Misawa, F., Yasuo, F., Okumura, Y., Ito, H. (2013). Metabolic Syndrome and Antipsychotic Polypharmacy. In: Ritsner, M. (eds) Polypharmacy in Psychiatry Practice, Volume II. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5799-8_8

Download citation

Publish with us

Policies and ethics

Search

Navigation